Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid

[1] Coleman RE(2001)Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165-176

[2] Coleman RE(2006)Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 6243s-6249s

[3] Dranitsaris G(2012)Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients Support Care Cancer 20 1353-1360

[4] Hatzimichael E(2004)Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment Int J Radiat Oncol Biol Phys 59 528-537

[5] van der Linden YM(1994)Pain and its treatment in outpatients with metastatic cancer N Engl J Med 330 592-596

[6] Lok JJ(2008)Prevalence of undertreatment in cancer pain. A review of published literature Ann Oncol 19 1985-1991

[7] Steenland E(2001)Bone metastases: approaches to management Semin Oncol 28 28-34

[8] Martijn H(2010)Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 5132-5139

[9] van Houwelingen H(2011)Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 813-822

[10] Marijnen CA(2011)Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 1125-1132

[1] Coleman RE(2001)Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165-176

[2] Coleman RE(2006)Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 6243s-6249s

[3] Dranitsaris G(2012)Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients Support Care Cancer 20 1353-1360

[4] Hatzimichael E(2004)Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment Int J Radiat Oncol Biol Phys 59 528-537

[5] van der Linden YM(1994)Pain and its treatment in outpatients with metastatic cancer N Engl J Med 330 592-596

[6] Lok JJ(2008)Prevalence of undertreatment in cancer pain. A review of published literature Ann Oncol 19 1985-1991

[7] Steenland E(2001)Bone metastases: approaches to management Semin Oncol 28 28-34

[8] Martijn H(2010)Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 5132-5139

[9] van Houwelingen H(2011)Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 813-822

[10] Marijnen CA(2011)Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 1125-1132